Sanofi has reached an agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, representing a 39% premium to Dynavax’s closing share price on December 23, 2025. Following the successful completion of the tender offer, any remaining Dynavax shares not tendered will also be converted to the same cash price. The deal will add Dynavax’s marketed adult hepatitis B vaccine, HEPLISAV-B®, and a phase 1/2 shingles vaccine candidate to Sanofi’s portfolio, strengthening its presence in adult immunization. The transaction has been unanimously approved by Dynavax’s board of directors and is expected to close in the first quarter of 2026, subject to customary closing conditions. Sanofi intends to fund the acquisition using its available cash resources.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-332264), on December 29, 2025, and is solely responsible for the information contained therein.